CallCredit Selects CallidusCloud CPQ
20.6.2017 14:00 | NASDAQ OMX
DUBLIN, Calif., June 20, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning and customer experience solutions announced today that CallCredit Ltd., a leading credit reference agency and consumer data management specialist, has selected CallidusCloud CPQ.
CPQ is delivered as part of CallidusCloud's Lead to Money suite, a SaaS suite designed to help businesses drive enterprise engagement, sales performance management and sales effectiveness throughout the sales cycle to close bigger deals, faster.
Callidus Software Inc. (NASDAQ:CALD), doing business as CallidusCloud®, is the global leader in cloud-based sales, marketing, learning and customer experience solutions. CallidusCloud enables organizations to accelerate and maximize their lead to money process with a complete suite of solutions that identify the right leads, ensure proper territory and quota distribution, enable sales forces, automate configure price quote, and streamline sales compensation -- driving bigger deals, faster. Approximately 5,000 leading organizations, across all industries, rely on CallidusCloud to optimize the lead to money process to close more deals for more money in record time.
About CallCredit Ltd.
CallCredit Ltd. is an expert in managing consumer data for businesses across every sector, within the UK and around the world. From financial services, retail and utilities to public sector, telecoms, insurance and many more, CallCredit's more than 1200 employees focus on developing innovative products and services to help businesses make smarter, more informed decisions throughout the customer lifecycle. Its leading-edge approach to deploying consumer information enables its clients to cost-effectively identify, engage and convert more new customers whilst optimizing existing customer profitability.
©2017 Callidus Software Inc. All rights reserved. Callidus, Callidus Software, the Callidus Software logo, CallidusCloud, the CallidusCloud logo, Clicktools, SURVE, syncfrog, TrueComp Manager, ActekSoft, ACom3, iCentera, Webcom, Litmos, the Litmos logo, LeadFormix, Rapid Intake, 6FigureJobs, and LeadRocket are trademarks, service marks, or registered trademarks of Callidus Software Inc.
Press Contacts: Chris Bucholtz CallidusCloud 925-251-2200 firstname.lastname@example.org
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Callidus Software via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Forterra Announces Second Quarter 2017 Earnings Schedule27.7.2017 22:30 | Pressmeddelande
IRVING, Texas, July 27, 2017 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release second quarter 2017 financial results before the market open on Thursday, August 10, 2017. A conference call to review financial results will also be held on Thursday, August 10, 2017 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Matt Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q2 2017 Forterra, Inc. Earnings Call Date: Thursday, August 10, 2017 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) Webcast: http://edge.media-server.com/m/p/uxphuyzt Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Parti
TGS Q2 2017 webcast and teleconference27.7.2017 18:14 | Pressmeddelande
ASKER, Norway, July 27, 2017 (GLOBE NEWSWIRE) -- TGS will release its Q2 2017 results at approximately 07:00 CEST on 3 August 2017. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at the Hotel Continental, Stortingsgata 24/26 in Oslo, Norway. The presentation is open to the public and can be followed live on the internet at www.tgs.com. The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. CEO Kristian Johansen and CFO Sven Børre Larsen will host a conference call on 3 August 2017 at 15:00 CEST (09:00 EDT). Attendees may want to call 5-10 minutes before to ensure registration and access. Norwegian attendees are invited to call + 800 51084 or + 47 2100 2610 International attendees are invited to call 0800 358 6377 or + 44 (0)330 336 9105 US attendees are invited to call +1 866-
Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36 | Pressmeddelande
VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850 VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30 | Pressmeddelande
Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after
Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22 | Pressmeddelande
Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00 | Pressmeddelande
- Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia - TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum